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ABSTRACT
Naked DNA is regarded as the safest and simplest method of
gene delivery. However, normally intravenously injected naked
plasmid DNA is rapidly eliminated from the blood. It has been
hypothesized that opsonins, a category of serum DNA-binding
proteins (SDBPs), label the injected plasmid DNA as foreign so
that it may be recognized and rapidly removed from the blood-
stream by liver nonparenchymal cells. Contrary to the hypoth-
esis, our data indicate that some SDBPs across multiple spe-
cies may have important dysopsonin properties, acting to
reduce liver uptake. Formation of SDBP and DNA complexes
was observed by agarose gel electrophoresis. An in vivo study
involving hepatic artery and portal vein occlusion in a mouse
model confirmed the activity of serum diminishing liver uptake
of DNA. Data using hydrodynamic gene transfer in the mouse
liver and in situ transfection in the mouse lung revealed that
serum proteins bound to DNA do not affect the biological
activity of the plasmid DNA. We have identified several SDBPs
with potential dysopsonin properties. The SDBPs with dysop-
sonin properties and DNA complexes may be further modified
and ultimately be developed into a novel DNA carrier system
favorable for systemic gene delivery.
Although nonviral vectors have been designed for systemic
gene therapy with increased stability in the bloodstream,
problems such as aggregation and inflammatory toxicity ex-
ist. With the administration of these vectors, inflammation is
characterized by increases in inflammation-inducing cyto-
kines, including tumor necrosis factor , interleukin 12, in-
terleukin 6, and interferon  (Sellins et al., 2005). Injection of
naked plasmid DNA is regarded as the safest and simplest
method of gene delivery. However, normally, intravenously
injected naked plasmid DNA is rapidly eliminated from the
blood and largely taken into liver nonparenchymal cells
(Kawabata et al., 1995; Yoshida et al., 1996; Nakamura et al.,
1998; Hisazumi et al., 2004), primarily endothelial cells and
not Kupffer cells where it is degraded (Liu et al., 2007), a
process that, in general, results in no gene expression. This
endothelial barrier to transfusion may be surmounted by
manual liver massage (Liu and Huang, 2002) similar to the
hydrodynamic-based transfection method studied in our lab-
oratory and others and enlargement of the fenestrae allowing
transfection of hepatocytes (Budker et al., 1998; Liu et al.,
1999; Zhang et al., 1999; Kobayashi et al., 2001; Lecocq et al.,
2003; Zhang et al., 2004). In an in vivo mouse model, the liver
could take up over 50% of 5 g of perfused plasmid DNA with
a maximum 25 g of plasmid DNA during a single pass with
a slower clearance rate compared with the rate of uptake.
Once the liver becomes saturated with plasmid DNA, addi-
tional naked DNA is available to transfect other organs.
Understanding the kinetics of DNA clearance after intrave-
nous injection is imperative to defining dosing parameters
and the sustained utilization of naked DNA as a gene ther-
apy vector (Liu et al., 2007). It is well known that some serum
DNA-binding proteins (SDBPs) or nucleases also degrade
plasmid DNA or are responsible for DNA clearance via the
intravenous route (Kawabata et al., 1995). We proposed here
that SDBPs may be involved in the liver uptake process as
opsonins.
Opsonins, a category of some serum proteins that enhance
phagocytosis by the reticuloendothelial system, have been
suggested to label the injected plasmid DNA as foreign so
that it may be recognized, removed from the bloodstream,
and degraded by nonparenchymal cells. In addition, opsonins
have been implicated in liver uptake of liposomes (Moghimi
and Patel, 1989). Serum proteins previously identified as
having opsonin effects include IgG, albumin, complement C3,
and various apolipoproteins (Yan et al., 2005).
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We originally hypothesized that SDBPs would bind to in-
jected plasmid DNA, labeling plasmid DNA as foreign and
resulting in uptake by liver nonparenchymal cells. Contrary
to the original hypothesis, additional data indicate that some
SDBPs may have important dysopsonin properties, acting to
reduce liver uptake, and protective properties against blood
degradation of plasmid DNA. We purified and identified po-
tential proteins with dysopsonin properties for future gene
delivery investigation. The relatively simple, nonviral gene
delivery system of natural serum proteins coupled with DNA
may aid with extending serum circulation time, reducing
toxicities inherent with lipoplex delivery, and improving de-
livery efficiency.
Materials and Methods
Liver Single-Pass Perfusion System. The single-pass perfu-
sion system developed by us (Liu et al., 1995) was used to test
plasmid DNA uptake by the liver. In brief, plasmid DNA (with or
without preincubation of serum) containing 1% 125I-labeled plasmid
DNA was added with 2 ml (pH 7.4, 37°C) of Krebs-Henseleit buffer,
and then perfused via the portal vein through the mouse liver (five
mice per group), which was previously prewashed with 3 ml of buffer
(prewarmed to 37°C). Mice (18–20 g body weight) were anesthetized
by 2,2,2-tribromoethanol (0.6 ml, 20 mg/ml i.p.) during the experi-
ment. The inferior vena cava was cut at the beginning of the exper-
iments to drain the blood and immediately followed by washing.
Unbound plasmid DNA in the liver was removed by washing the
perfused liver with 5 ml of buffer via the same route. The perfusion
rate was kept constant at 2 ml/min. The amount of plasmid DNA
taken up by the liver was determined by measuring the 125I radio-
activity in the liver. The serum was prepared just before use as
follows: mouse blood was collected by retro-orbital bleeding and
allowed to clot at room temperature for 20 min, then it was centri-
fuged at 2000g for 20 min at 4°C, and the serum (supernatant) was
collected.
Iodination and in Vivo Distribution of DNA. Plasmid DNA
was labeled with 125I according to a published method (Zhang et al.,
2006). In brief, in an IODO-GEN precoated iodination tube (Pierce
Chemical, Rockford, IL), the following reagents were added: 50 l of
2 g/l DNA, 30 l of 0.35 M sodium acetate, pH 4.0, and 600 pmol
of 125I-labeled sodium iodine. The mixture was incubated at 50°C for
30 min. After chilling on ice, 10 l of 1 N NaOH was added, and then
free iodine was removed by use of a Bio-Spin 30 column (Bio-Rad
Laboratories, Hercules, CA). After injection of DNA (125I-labeled
DNA diluted 1:100 with unlabeled plasmid DNA), the mice were
killed at 2 min, and the organs, such as the lung, liver, spleen, and
blood, were collected. The collected blood and organs were subjected
to assay for 125I radioactivity with use of a -counter. The distribu-
tion of DNA in the blood was estimated with the assumption that the
total amount of blood is approximately 7.3% of the body weight.
Examination of Dysopsonin Activity in Living Animal
Model. Mice of 15 g body weight were anesthetized with an intra-
peritoneal injection of 8 mg of 2,2,2-tribromoethanol. Liver was ex-
posed through ventral midline incision. Mice were intravenously
(tail vein) injected with plasmid DNA in 100 l saline (0.9% NaCl)
immediately after occlusion of blood flow through the liver. The
injection speed for most experiments was 100 l/s. The occlusion of
blood flow was performed by a simple clip at the combination of the
portal vein and hepatic artery. The clip was released immediately
after injection, and the blood sample and other organs were collected
2 min after the release of the clip.
Purification and Identification of SDBPs. Purification of SDBPs
was initiated by use of a dsDNA-cellulose column (GE Healthcare,
Little Chalfont, Buckinghamshire, UK) according to manufacturer’s
protocol. However, a substantial amount of SDBPs remained bound
to the DNA-cellulose column after elution of SDBPs with 1 to 2 M
NaCl as detected with the Coomassie Plus Protein Assay Reagent
Kit (Pierce Chemical). We developed a new method for identifying
SDBPs by digesting DNA (in the dsDNA-cellulose column incubated
with mouse serum) with DNase I to release SDBPs. In brief, 200 l
of mouse serum was added to 200 l of dsDNA-cellulose containing
125 g of DNA and gently vortexed for 2 min. The mixture was
centrifuged at 3000g to remove the supernatant. Pellets were
washed six times with equilibration buffer (10 mM Tris-HCl, pH 7.5,
0.1 mM dithiothreitol, 5% glycerol (v/v), 0.1 M NaCl, and 0.1 mM
EDTA) and then washed three times with phosphate-buffered saline
1 buffer. All processes above were completed at 4°C. Subsequently,
pellets were incubated with DNase I at 37°C for 1 h. To minimize the
DNase appearance in the SDS-PAGE gel because the DNase I band
may overlap with SDBPs, a low concentration of DNase I (0.2 g) and
longer digestion time (1 h) were used. After digestion, the superna-
tant was loaded onto a Tris-HCl 12% polyacrylamide gel (Bio-Rad
Laboratories). Proteins were visualized with Coomassie blue stain-
ing, and those bands unique to the dsDNA-cellulose and mouse
serum lane were identified by mass spectrophotometry at the Hooker
Proteomics Center at the University of North Carolina.
Results
The Role of Serum in Liver Uptake of DNA. In gen-
eral, intravenous injection of naked plasmid DNA results in
no gene expression even in the liver where the highest up-
take is observed. Injected plasmid DNA is taken up exten-
sively by liver nonparenchymal cells. After intravenous in-
jection in a mouse model, as shown in Fig. 1, both intact
supercoiled plasmid DNA and DNA fragments that were
amplified by PCR (Hofman et al., 2001) were distributed
mostly to the liver with a small amount remaining in the
blood and other compartments, including lung, heart, kidney,
and spleen. The liver took up over 50% of DNA 2 min after
injection of 5 g of DNA. Less than 20% of the injected DNA
was detected in blood, and less than 2% was detected in other
organs. A similar uptake pattern existed for both intact plas-
mid and PCR fragment DNA, which indicates that liver up-
take of DNA is independent of the size of DNA. To observe
the role of the extent of naked DNA uptake by the liver, a
single-pass liver perfusion system was used in a mouse
model. It is noteworthy that DNA uptake by the liver was
Fig. 1. Distribution of DNA. After intravenous injection in a mouse
model, intact supercoiled DNA and DNA fragments were distributed
mostly to the liver with a smaller amount of DNA retained in the blood
compartment. Minimal amounts of DNA were detected in the spleen,
kidney, lung, and heart.
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reduced after perfusion with plasmid DNA incubated with
mouse serum compared with perfusion with naked plasmid
DNA. Furthermore, increasing the ratio of serum to plasmid
DNA during the incubation process resulted in significantly
decreased uptake of plasmid DNA when perfused to the
mouse liver. When 5 g of plasmid DNA was complexed with
2 l of serum, plasmid DNA uptake was decreased from 60%
(plasmid DNA alone) to 43% (p  0.05), and further de-
creased to less than 30% (p  0.01) at the ratio of 1:1 of
DNA/serum (Fig. 2a). This decreased liver uptake is not
limited to the mouse model, because serum from rat, bovine,
and human species also inhibits DNA liver uptake (Fig. 2b).
We hypothesized that the decreased uptake of DNA incu-
bated with serum is due to a dysopsonin mechanism in that
some serum proteins bind to DNA such that the DNA is
protected from being recognized by nonparenchymal cells.
Indeed, a gel shift assay demonstrated the formation of
SDBP and DNA complexes. These SDBP and plasmid DNA
complexes (SDBPs/DNA) formed a distinct band character-
ized by decreased gel mobility compared with plasmid DNA
alone (Fig. 3).
Examination of the Dysopsonin Activity of SDBPs
in Vivo. SDBPs theoretically must bind to DNA to exhibit
their dysopsonin activity. However, when DNA is directly
injected into the bloodstream, SDBPs do not have enough
time to bind the DNA because the DNA will be quickly taken
up by the liver and eliminated from blood. Presumably, if the
binding condition is provided for SDBPs, their in vivo dysop-
sonin activity should be observed. We, therefore, designed in
vivo studies to confirm the activity of serum diminishing liver
uptake of DNA. The first study was to preincubate DNA with
serum before the injection. Compared with a control, the
DNA preincubated with serum (SDBPs/DNA) had a decrease
in percentage taken up by the liver and an increase of per-
centage in the blood. The second study was to provide a
retention time for SDBPs binding the injected DNA (see
Materials and Methods), in which the DNA, after the injec-
tion, was allowed to circulate in blood for a few minutes but
was not passed through the liver. By blocking the hepatic
artery and portal vein, access to the liver was effectively
impeded via the intravenous route, and serum proteins with
dysopsonin properties in the mouse model were provided
additional time to bind DNA before clamp release and liver
uptake (Fig. 4). By doing so, an even greater percentage
decrease in liver uptake was examined when the portal vein
and hepatic artery were temporarily clamped in the in vivo
model, followed by naked DNA administration (Fig. 4). One
question may be raised that transiently blocking blood
Fig. 2. a, inhibition of DNA uptake by the liver by use of various ratios of
mouse serum to DNA (p  0.05, 0.01). b, inhibition of DNA uptake by the
liver by use of various ratios of serum of other species.
Fig. 3. Mobility shift assay of SDBPs and DNA complexes. The complexes
form a distinct band in the right lane band characterized by decreased gel
mobility compared with plasmid DNA alone in the left lane.
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through the liver may change liver function such that the
uptake of DNA could be decreased. This possibility was ruled
out by measuring the uptake of DNA that was intravenously
injected after the performance of clamping and releasing the
blood flow through the liver, which showed no difference in
liver DNA uptake compared with that of intact mice (data not
shown). We also transferred the SDBPs/DNA to the liver and
lung to examine whether the gene transfer efficiency is af-
fected by SDBPs. Data using hydrodynamic gene transfer in
the mouse liver (Liu et al., 1999) and lung gene transfer with
sequential injection (Song et al., 1998; Tan et al., 2001)
revealed that serum proteins bound to DNA do not affect the
biological activity of the plasmid DNA (Fig. 5). During se-
quential injection, cationic liposomes were injected into a
mouse model followed by injection of DNA after a time inter-
val. Cationic liposomes form aggregates after exposure to
blood or serum because of electrostatic interactions, a conse-
quence leading to trapped DNA after a second injection of a
gene therapy product. Similar to our study in which blood
flow was blocked through the liver, sequential injection min-
imized the flushing effect of blood in vivo and prolonged the
exposure time of DNA to target cells for enhanced gene
transfer in the lung (Song et al., 1998; Tan et al., 2001).
Identification of SDBPs. Next, we identified the SDBPs
from mouse serum. We purified proteins with potential
dysopsonin properties by use of dsDNA cellulose incubated
with mouse serum, followed by digestion with DNase I to
release SDBPs. We initially had difficulty in completely elut-
ing SDBPs from the dsDNA. After elution with 1 to 2 M NaCl
per the GE Healthcare protocol, a substantial amount of
SDBPs remained bound to the DNA-cellulose, detected via
the Coomassie Plus Protein Reagent Kit (Pierce Chemical). A
new method was developed to identify SDBPs, in which DNA
(dsDNA-cellulose/mouse serum) was digested with DNase I
to release SDBPs. Proteins were visualized by use of a SDS-
PAGE gel. In Fig. 6A, three dominant SDBP bands can be
visualized in lane 2 (arrows a, b, and c) with sizes of approx-
imately 18 kDa, 20 kDa, and 240 kDa, which were not
present in lanes 1 and 3. Lanes 1 and 2 were from samples of
cellulose/mouse serum (control) and dsDNA-cellulose/mouse
serum, respectively. Lane 3 was from the sample of equal
amounts of DNase used in lanes 1 and 2. Lane 4 was from
mouse serum (0.6 l) alone. Similar bands of SDBPs were
detected in human serum from two individuals in Fig. 6B
(circled bands in lanes 5 and 6). The three major protein
Fig. 4. In vivo serum effect on DNA uptake. Compared with a control,
DNA preincubated with serum had a decreased percent uptake in the
liver in a mouse model. An even greater percentage decrease in liver
uptake was visualized when the portal vein (PV) and hepatic artery (HA)
were temporarily clamped, allowing serum proteins with dysopsonin
properties additional time to bind DNA before clamp release and expo-
sure to liver nonparenchymal cells.
Fig. 5. Biological activity of plasmid DNA. Data using hydrodynamic
gene transfer in the mouse liver and in situ transfection in mouse lung
reveal that serum DNA-binding proteins do not affect the biological
activity of plasmid DNA. RLU, relative light units.
Fig. 6. A, SDS-PAGE analysis of serum DNA-binding proteins from
mouse serum. Three dominant SDBPs can be visualized in lane 2 con-
taining the dsDNA-cellulose/mouse serum with approximate sizes of 18
kDa (c), 20 kDa (b), and 240 kDa (c). Lane 1 contains the cellulose/mouse
serum control, whereas lane 3 is from the sample of equal amounts of
DNase used in lanes 1 and 2. Lane 4 is from the mouse serum (0.6 l)
alone. B, SDS-PAGE analysis of serum DNA-binding proteins from hu-
man serum. Lanes 1 and 2 contain DNase, whereas lanes 3 and 4 contain
the cellulose/human serum control. Lanes 5 and 6 are from dsDNA-
cellulose/human serum. Similar bands of serum DNA-binding proteins
identified with arrows a, b, and c in A were detected with human serum
from two individuals.
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bands from Fig. 6A were identified with mass spectrophotom-
etry analysis. Identified SDBPs included platelet factor 4,
histone 4, cytoplasmic -actin, 1-globin, albumin 1, throm-
bospondin 1 precursor, hemoglobin -chains, and histone-
like proteins.
Discussion
In general, intravenous injection of naked plasmid DNA
results in no gene expression, even in the liver where the
highest uptake of gene delivery occurs. It has been suggested
that some SDBPs exist as scavengers to remove DNA from
the serum. We hypothesized that SDBPs would bind to in-
jected plasmid DNA, labeling plasmid DNA as foreign for
uptake by liver nonparenchymal cells. Contrary to the orig-
inal hypothesis, additional data indicate that some SDBPs
may have important dysopsonin properties, acting to reduce
liver uptake, and protective properties against blood degra-
dation of plasmid DNA. Therefore, we proposed a unique
nonviral gene delivery system by use of serum proteins with
dysopsonin properties. Extending the in vivo circulation time
of plasmid DNA for delivery is instrumental to gene therapy,
because plasmid DNA must be protected from degradation
when systemically administered. Use of innate serum pro-
teins with dysopsonin properties may also enhance the po-
tential for systemic gene delivery by reducing toxicity, in
particular, immunogenicity, and through ease of amplifica-
tion. Another advantage to using serum proteins with dysop-
sonin properties is that the biological activity of the plasmid
DNA does not seem to be compromised, as evidenced through
hydrodynamic gene transfer in the mouse liver and in situ
transfection in the mouse lung.
Although nonviral liposomal vectors have been designed
for systemic gene therapy with increased stability in the
bloodstream, problems such as aggregation, inflammatory
toxicity, and gene delivery inefficiency exist. Gene delivery
methods should ideally protect against degradation by nucle-
ases, transport the gene across plasma and nuclear mem-
branes, and be devoid of harmful effects (Gao et al., 2007). In
this study, we identified SDBPs with potential dysopsonin
properties including platelet factor 4, histone 4, cytoplasmic
-actin, 1-globin, albumin 1, thrombospondin 1 precursor,
hemoglobin -chains, and histone-like proteins. An optimal
gene delivery protein candidate for conjugation to DNA must
be isolated and further amplified through a bacterial vector.
The SDBP with dysopsonin properties and DNA complexes may
be modified further through measures such as polyethylene
glycolation and conjugation with targeting ligands to enhance
specificity and cellular uptake for DNA transfer, while minimiz-
ing toxicity in vivo after identification of essential protein bind-
ing elements. These complexes ultimately may be developed
into a novel DNA carrier system favorable for systemic gene
delivery with prolonged circulation time as a result of decreased
degradation.
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